Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been given a consensus recommendation of “Moderate Buy” by the ten analysts that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $25.1875.

Several research firms recently commented on ROIV. Guggenheim reiterated a “buy” rating and issued a $28.00 price objective on shares of Roivant Sciences in a research report on Thursday, December 18th. The Goldman Sachs Group upped their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 15th. HC Wainwright increased their price target on shares of Roivant Sciences from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Roivant Sciences in a research note on Thursday, January 22nd.

Insider Buying and Selling

In other news, Director Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $20.23, for a total value of $26,299,000.00. Following the transaction, the director directly owned 18,047,727 shares of the company’s stock, valued at $365,105,517.21. The trade was a 6.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Richard Pulik sold 406,731 shares of Roivant Sciences stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $22.43, for a total transaction of $9,122,976.33. Following the transaction, the chief financial officer owned 239,413 shares in the company, valued at $5,370,033.59. The trade was a 62.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 12,332,392 shares of company stock worth $266,393,645 over the last 90 days. Company insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

Several institutional investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp increased its holdings in shares of Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after acquiring an additional 1,148 shares during the period. Allworth Financial LP grew its position in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares in the last quarter. Bessemer Group Inc. raised its position in shares of Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after buying an additional 543 shares in the last quarter. CWM LLC lifted its stake in shares of Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after acquiring an additional 920 shares during the period. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Roivant Sciences by 59.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,600 shares of the company’s stock valued at $78,000 after acquiring an additional 1,345 shares in the last quarter. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Stock Performance

ROIV stock opened at $22.02 on Friday. The stock has a market capitalization of $15.31 billion, a PE ratio of -39.32 and a beta of 1.22. The company has a fifty day moving average of $21.87 and a 200-day moving average of $17.32. Roivant Sciences has a one year low of $8.73 and a one year high of $23.91.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.